ASHM recognises the vital role that practitioners working in drug and alcohol settings or with people who use drugs play in the testing, diagnosis, treatment and care of those at risk of and living with viral hepatitis. Our Viral Hepatitis and Substance Use Program aims:
To strengthen the capacity of healthcare professionals working in drug and alcohol clinics or with people who use drugs to effectively test for, treat and manage HCV infection
To support partner organisations, including community organisations, within the sector to develop, deliver and evaluate education on viral hepatitis
To advocate for safe and equitable care, free of stigma and discrimination for people with viral hepatitis
Facilitating scale up of HCV testing and treatment in drug and alcohol clinics
Developed in collaboration with the Kirby Institute
3-part education program including online learning, full day face-face workshop and capacity strengthening toolkit
RACGP and ACCRM accredited
Facilitating scale up of HCV testing, referral and treatment in needle and syringe programs
2-part education program including online learning and 3-hour face-face workshop
Identification, treatment and support for pharmaceutical opioid dependence
RACP and Pharmaceutical Society of Australia accredited
ASHM has collaborated with the International Network on Hepatitis in Substance Users (INHSU) to adapt and deliver the Hepatitis C in Primary Care and Drug and Alcohol Settings Education Program, internationally.
INHSU is a not-for-profit, member-based organisation dedicated to scientific knowledge exchange, knowledge translation, and advocacy focused on hepatitis C prevention and care among people who use drugs. To find out more please visit www.inhsu.org.
In close partnership with local organisations, ASHM and INHSU tailor and translate the education program to ensure materials and resources meet the needs of practitioners, are in-line with local guidelines and appropriately support increased HCV screening, linkage-to-care and treatment for people living with HCV.